Hikma and Civica seek to tackle US generic shortages

London-listed drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed an agreement with Civica Rx, a non-profit that was set up last year to reduce chronic generic drug shortages in the USA.

The five-year agreement is for the manufacture and supply of Civica’s growing membership of US health systems with medications that are often in short supply in hospitals.

"Our partnership will help us make an impact as quickly as possible"Hikma will produce 14 essential sterile injectable medications as a private label distributor, using its Abbreviated New Drug Application and Civica’s labeling and National Drug Code.